Desloratadine: A review of pharmacology and clinical efficacy in allergic rhinitis and urticaria

Therapy

Volumn 5, Issue 6, 2008, Pages 817-828

  Dizdar, Evrim Alyamac ^a   Sekerel, Bulent Enis ^a   Tuncer, Ayfer ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Allergic rhinitis; Allergy; Chronic idiopathic urticaria; Desloratadine; Histamine; Inflammation

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CIMETIDINE; DESLORATADINE; DIPHENHYDRAMINE; ERYTHROMYCIN; FEXOFENADINE; FLUOXETINE; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MONTELUKAST; PLACEBO; REDITABS; TERFENADINE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; BLURRED VISION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITION; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRY EYE; DYSMENORRHEA; ELECTROCARDIOGRAM; FATIGUE; FORCED EXPIRATORY VOLUME; HUMAN; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; PAW EDEMA; PHARYNGITIS; QT INTERVAL; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; TABLET FORMULATION; URINE RETENTION; URTICARIA; XEROSTOMIA;

EID: 59749088329     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.5.6.817     Document Type: Review

References (90)

1. Reed SD, Lee TA, McCrory DC: The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 22(6), 345-361 (2004).
2. Civelek E, Soyer OU, Gemicioglu B, Sekerel BE: Turkish physicians' perception of allergic rhinitis and its impact on asthma. Allergy 61(12), 1454-1458 (2006).
3. Linna O, Kokkonen J, Lukin M: A 10-year prognosis for childhood allergic rhinitis. Acta Paediatr. 81(2), 100-102 (1992).
4. Kocabas CN, Civelek E, Sackesen C et al. Burden of rhinitis in children with asthma. Pediatr. Pulmonol. 40(3), 235-240 (2005).
5. Bousquet J, Khaltaev N, Cruz AA et al.: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2) LEN and AllerGen). Allergy 63 (Suppl. 86), 8-160 (2008).
6. Fokkens W, Lund V, Mullol J: European position paper on rhinosinusitis and nasal polyps 2007. Rhinol. Suppl. (20), 1-136 (2007).
7. DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am. J. Clin. Dermatol. 8(5), 271-283 (2007).
8. Zuberbier T, Bindslev-Jensen C, Canonica W et al.: EAACI/GA2LEN/ EDF guideline: management of urticaria. Allergy 61(3), 321-331 (2006).
9. Molet S, Gosset P, Lassalle P, Czarlewski W. Tonnel AB: Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin. Exp. Allergy 27(10), 1167-1174 (1997).
10. Kreutner W, Hey JA, Anthes J, Barnett A, Young S, Tozzi S: Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 50(4), 345-352 (2000).
11. Anthes JC, Gilchrest H, Richard C et al.: Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur. J. Pharmacol. 449 (3), 229-237 (2002).
12. Kreutner W, Hey JA, Chiu P, Barnett A: Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 50(5), 441-448 (2000).
13. Howell G, 3rd, West L, Jenkins Q, Lineberry B, Yokurn D, Rockhold R: In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine. BMC Pharmacol. 5, 13 (2005).
14. Murdoch D, Goa KL, Keam SJ: Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs 63(19), 2051-2077 (2003).
15. Vuurman EF, Rikken GH, Muntjewerff ND, dc Halleux F, Ramaekers JG: Effects of desloratadine, diphenhydamine, and placebo on driving performance and psychomotor performance measurements. Eur. J. Clin. Pharmacol. 60(5), 307-313 (2004).
16. Liu H, Zheng Q, Farley JM: Antimuscarinic actions of antihistamines on the heart. J. Biomed. Sci. 13(3), 395-401 (2006).
17. Henz BM: The pharmacologic profile of desloratadine: a review. Allergy 56(Suppl. 65), 7-13 (2001).
18. Prenner B, Kim K, Gupta S et al.: Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. Expert Opin. Drug Saf. 5(2), 211--223 (2006).
19. Handley D, McCullough J, Fang Y: Descarboethoxyloratadine, a metabolite of loratadine, is a superior antihistamine. Ann. Allergy Asthma Immunol. 78, 143 (1997).
20. Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G, Marone G: Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological felease of mediators from human Fc epsilon RI+ cells. Clin. Exp. Allergy. 27(5), 559-567 (1997).
21. Vignola AM, Crampette L, Mondain M et al.: Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 50(3), 200-203 (1995).
22. Bayram H, Devalia JL, Khair OA et al.: Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured human bronchial epithelial cells. J. Allergy Clin. Immunol. 104(1), 93-99 (1999).
23. Kleine-Tebbe J, Josties C, Frank G et al.: Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J. Allergy Clin. Immunol. 93(2), 494-500 (1994).
24. Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W: Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin. Exp. Allergy. 31(9), 1369-1377 (2001).
25. Agrawal DK: Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin. Investig. Drugs. 10(3), 547-560 (2001).
26. Agrawal DK: Anti-inflammatory properties of desloratadine. Clin. Exp. Allergy. 34(9), 1342-1348 (2004).
27. DuBuske LM: Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. Expert Opin. Pharmacother. 6(14), 2511-2523 (2005).
28. Bryce PJ, Geha R, Oettgen HC: Desloraradine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. J. Allergy Clin. Immunol. 112(1), 149-158 (2003).
29. Gelfand EW: Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists. Am. J. Med. 113(Suppl. 9A), 2S-7S (2002).
30. Reinartz SM, Overbeek SE, Kleinjan A et al.: Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. Allergy 60(10), 1301-1307 (2005).
31. Cyr MM, Hayes LM, Crawford L, Baatjes AJ, Keith PK, Denburg JA: The effect of desloratadine on eosinophill/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study. Int. Arch. Allergy Immunol. 138(3), 209-216 (2005).
32. Papi A, Papadopoulos ng, Stanciu LA, Degitz K, Holgate ST, Johnston SL: Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J. Allergy Clin. Immunol. 108(2), 221-228 (2001).
33. Roumestan C, Henriquet C, Gougat C et al.: Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin. Exp. Allergy. 38(6), 947-956 (2008).
34. Affrime M, Gupta S, Banfield C, Cohen A: A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin. Pharmacokinet. 41(Suppl. 1), 13-19 (2002).
35. Gupta S, Banfield C, Affrime M et al.: Desloratadine demonstrates dose proportionality in healthy adults after single doses. Clin. Pharmacokinet. 41 (Suppl. 1), 1-6 (2002).
36. Banfield C, Gupta S, Affrime M: Grapefruit juice reduces the bioavailability of fexofenadine but not desloratadine. Allergy 55(Suppl. 63), 199 (2000).
37. Gupta S, Banfield C, Affrime M, Marbury T, Padhi D, Glue P: Oral bioavailability of desloratadine is unaffected by food. Clin. Pharmacokinet. 41(Suppl. 1), 7-12 (2002).
38. Gupta S, Kantesaria B, Wang Z, Khalilieh S: Pharmacokinetics of desloratadine in poor metabolizers. Ann. Allergy Asthma Immunol. 94, 249 (2005).
39. Gupta S, Khalilieh S, Kantesaria B, Banfield C: Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br. J. Clin. Pharmacol. 63(5), 534-540 (2007).
40. Gupta SK, Kantesaria B, Banfield C, Wang Z: Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. Br. J. Clin. Pharmacol. 64(2), 174-184 (2007).
41. Gupta SK, Kantesaria B, Wang Z: Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment. J. Clin. Pharmacol. 47(10), 1283-1291 (2007).
42. Nayak AS, Schenkel E: Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 56(11), 1077-1080 (2001).
43. Bhatia S, Baroody FM, deTineo M, Naclerio RM: Increased nasal airflow with budesonide compared with desloratadine during the allergy season. Arch. Otolaryngol. Head Neck. Surg. 131(3), 223-228 (2005).
44. Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG: Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: resulis of a single-center, placebo-controlled trial. Ann. Allergy Asthma Immunol. 96(2), 363-368 (2006).
45. Pradalier A, Neukirch C, Dreyfus I, Devillier P: Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy 62(11), 1331-1334 (2007).
46. Berger WE, Schenkel EJ, Mansfield LE: Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann. Allergy Asthma Immunol. 89(5), 485-491 (2002).
47. Salmun LM, Lorber R: 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam. Pract. 3, 14 (2002).
48. Horak F, Stubner UP, Zieglmayer R, Harris AG: Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J. Allergy Clin. Immunol. 109(6), 956-961 (2002).
49. Raphael GD, Angello JT, Wu MM, Druce HM: Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 96(4), 606-614 (2006).
50. Day JH, Briscoe MP, Rafeiro E, Ratz JD: Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int. J. Clin. Pract. 58(2), 109-118 (2004).
51. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA: Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin. Exp. Allergy 34(6), 958-964 (2004).
52. Ciprandi G, Tosca MA, Milanese M, Schenone G, Ricca V: Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: histamine and leukotriene antagonism. Eur. Ann. Allergy Clin. Immunol. 36(2), 67-70, 72 (2004).
53. Willson AM, Haggart K, Sims EJ, Lipworth BJ: Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin. Exp. Allergy 32(10), 1504-1509 (2002).
54. Berger WE, Lumry WR, Meltzer EO, Pearlman DS: Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc. 27(3), 214-223 (2006).
55. Baena-Cagnani CE, Berger WE, DuBuske LM et al.: Comparative effects of desloratadine versus montelukast on asthma symptoms and use of β 2-agonists in patients with seasonal allergic rhinitis and asthma. Int. Arch. Allergy Immunol. 130(4), 307-313 (2003).
56. Lee DK, Haggart K, Currie GP, Anderson SD, Lipworth BJ: The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. Br. J. Clin. Pharmacol. 55(6), 639-642 (2003).
57. Dizdar EA, Sekerel BE, Keskin O et al.: The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis. Int. J. Pediatr. Otorhinolarynkol. 71(6), 843-849 (2007).
58. Kim K, Sussman G, Hebert J, Lumry W, Lutsky B, Gates D: Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 96(3), 460-465 (2006).
59. Simons FE, Prenner BM, Finn A, Jr. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J. Allergy Clin. Immunol. 111(3), 617-622 (2003).
60. Ciprandi G, Cirillo I, Vizzaccaro A et al.: Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int. Immunopharmacol. 5(13-14), 1800-1808 (2005).
61. Holmberg K: Effectiveness of desloratadine in releiving morning symptoms of perennial allergic rhinitis. Proceedings of the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology. Anaheim, CA, USA (2005).
62. Tonnel AB, Holmberg K, Sauvage N, Enander I: Desloratadine improves the health-related quality of life in persistent allergic rhinitis. Proceedings of the 23rd Congress of the European Academy of Allergology and Clinical Immunology. Amsterdam, The Netherlands (2004).
63. Canonica GW, Tarantini F, Compalati E, Penagos M: Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 62(4), 359-366 (2007).
64. Lee DK, Gardiner M, Haggart K, Fujihara S, Lipworth BJ: Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin. Exp. Allergy 34(4), 650-653 (2004).
65. Passalacqua G, Guerra L, Compalati E et al.: Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int Arch Allergy Immunol. 135(2), 143-147 (2004).
66. Passalacqua G, Canonica GW: A review of the evidence from comparative studies of levocetirizine and desloratadinie for the symptoms of allergic rhinitis. Clin. Ther. 27(7), 979-992 (2005).
67. Ciebiada M, Gorska-Ciebiada M, DuBuske LM, Gorski P: Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann. Allergy Asthma Immunol. 97(5), 664-671 (2006).
68. Davis BE, Todd DC, Cockcroft DW: Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen. J. Allergy Clin. Immunol. 116(4), 768-772 (2005).
69. Antonijoan R, Garcia-Gca C, Puntes M et al.: Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg), a randomized, double-blind, doable-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults. Clin. Ther. 29(5), 814-822 (2007).
70. Frossard N, Strolin-Benedetti M, Purohit A, Pauli G: Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br. J. Clin. Pharmacol. 65(2), 172-179 (2008).
71. Juhlin L: Inhibition of cold urticaria by desloratadine. J. Dermatolog. Treat. 15(1), 51-59 (2004).
72. Nettis E, Colanardi MC, Soccio AL, Ferrannini A, Vacca A: Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. Br. J. Dermatol. 155(6), 1279-1282 (2006).
73. Glass D, Harper A: Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. BMC Family Practice. 13(4), 10-16 (2003).
74. Bachert C, Virchow C, Plenker A: Desloratadine in the treatment of seasonal allergic rhinitis: results of a large observational study. Clin. Drug Invest. 22(Suppl. 2), 43-52 (2002).
75. Ortonne JP, Grob JJ, Auquier P, Dreyfus I: Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am. J. Clin. Dermatol. 8(1), 37-42 (2007).
76. Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D: Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J. Am. Acad. Dermatol. 48(4), 535-541 (2003).
77. Bloom M, Staudinger H, Herron J: Safety of desloratadine syrup in children. Curr. Med. Res. Opin. 20(12), 1959-1965 (2004).
78. Prenner B, Ballona R, Bueso A et al. Safety of desloratadine syrup in children six months to younger than 2 years of age: a randomized, double-blinded, placebo-controlled study. Pediatric Asthma, Allergy & Immunology. 19(2), 91-99 (2006).
79. Spangler DL, Brunton S: Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis. South Med. J. 99(6), 593-599 (2006).
80. Ridout F, Meadows R, Johnsen S, Hindmarch I: Effects of desloratadine 5,10 and 20 mg, and promethazine 25 mg on cognitive and psychomotor performance. Ann. Allergy Asthma Immunol. 90, 124 (2003).
81. Layton D, Wilton L, Boshier A, Cornelius V, Harris S, Shakir SA: Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf. 29(10), 897-909 (2006).
82. Scharf M, Kay G, Rikken G: Desloratadine has no effect on wakefulness or psychomotor performance. Allergy 55 (Suppl. 63), 280 (2000).
83. Nicholson AN, Handford AD, Turner C, Stone BM: Studies on performance and sleepiness with the HI-antihistamine, desloratadine. Aviat. Space Environ. Med. 74(8), 809-815 (2003).
84. Wilken JA, Kane RL, Ellis AK et al.: A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Ann. Allergy Asthma Immunol. 91(4), 375-385 (2003).
85. Valk PJ, Van Roon DB, Simons RM, Rikken G: Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat. Space Environ. Med. 75(5), 433-438 (2004).
86. Scharf M, Berkowitz D: Effects of desloratadine and alcohol coadministration on psychomotor performance. Curr. Med. Res. Opin. 23(2), 313-321 (2007).
87. Grob JJ, Auquier P, Dreyfus I, Ortonne JP: Quality of life in adults with chronic idiopathic urticaria receiving destoratadine: a randomized, double-blind, multicentre, placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 22(1), 87-93 (2008).
88. Ring J, Hein R, Gauger A, Bronsky E, Miller B: Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int. J. Dermatol. 40(1), 72-76 (2001).
89. Di Lorenzo G, Pacor ML, Mansueto P et al.: Randomized placebo-controlled trial comparing desloratadire and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J. Allergy Clin. Immunol. 114(3), 619-625 (2004).
90. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A: Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin. Exp. Allergy. 34(9), 1401-1407 (2004).